133 related articles for article (PubMed ID: 30718665)
1. Oxo-aglaiastatin-Mediated Inhibition of Translation Initiation.
Itoua Maïga R; Cencic R; Chu J; Waller DD; Brown LE; Devine WG; Zhang W; Sebag M; Porco JA; Pelletier J
Sci Rep; 2019 Feb; 9(1):1265. PubMed ID: 30718665
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.
Bordeleau ME; Robert F; Gerard B; Lindqvist L; Chen SM; Wendel HG; Brem B; Greger H; Lowe SW; Porco JA; Pelletier J
J Clin Invest; 2008 Jul; 118(7):2651-60. PubMed ID: 18551192
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.
Oblinger JL; Burns SS; Huang J; Pan L; Ren Y; Shen R; Kinghorn AD; Welling DB; Chang LS
Exp Neurol; 2018 Jan; 299(Pt B):299-307. PubMed ID: 28610844
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of small molecules targeting eIF4A.
Naineni SK; Itoua Maïga R; Cencic R; Putnam AA; Amador LA; Rodriguez AD; Jankowsky E; Pelletier J
RNA; 2020 May; 26(5):541-549. PubMed ID: 32014999
[TBL] [Abstract][Full Text] [Related]
5. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.
Chu J; Zhang W; Cencic R; Devine WG; Beglov D; Henkel T; Brown LE; Vajda S; Porco JA; Pelletier J
Cell Chem Biol; 2019 Nov; 26(11):1586-1593.e3. PubMed ID: 31519508
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.
Chu J; Galicia-Vázquez G; Cencic R; Mills JR; Katigbak A; Porco JA; Pelletier J
Cell Rep; 2016 Jun; 15(11):2340-7. PubMed ID: 27239032
[TBL] [Abstract][Full Text] [Related]
7. Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas.
Zhang X; Bi C; Lu T; Zhang W; Yue T; Wang C; Tian T; Zhang X; Huang Y; Lunning M; Hao X; Brown LE; Devine WG; Vose J; Porco JA; Fu K
Leukemia; 2020 Jan; 34(1):138-150. PubMed ID: 31171817
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol.
Cencic R; Carrier M; Galicia-Vázquez G; Bordeleau ME; Sukarieh R; Bourdeau A; Brem B; Teodoro JG; Greger H; Tremblay ML; Porco JA; Pelletier J
PLoS One; 2009; 4(4):e5223. PubMed ID: 19401772
[TBL] [Abstract][Full Text] [Related]
9. Targeting the eIF4A RNA helicase as an anti-neoplastic approach.
Chu J; Pelletier J
Biochim Biophys Acta; 2015 Jul; 1849(7):781-91. PubMed ID: 25234619
[TBL] [Abstract][Full Text] [Related]
10. A parasitic fungus employs mutated eIF4A to survive on rocaglate-synthesizing
Chen M; Kumakura N; Saito H; Muller R; Nishimoto M; Mito M; Gan P; Ingolia NT; Shirasu K; Ito T; Shichino Y; Iwasaki S
Elife; 2023 Feb; 12():. PubMed ID: 36852480
[TBL] [Abstract][Full Text] [Related]
11. Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A.
Cencic R; Robert F; Galicia-Vázquez G; Malina A; Ravindar K; Somaiah R; Pierre P; Tanaka J; Deslongchamps P; Pelletier J
Blood Cancer J; 2013 Jul; 3(7):e128. PubMed ID: 23872707
[TBL] [Abstract][Full Text] [Related]
12. Selective targeting of the DEAD-box RNA helicase eukaryotic initiation factor (eIF) 4A by natural products.
Shen L; Pelletier J
Nat Prod Rep; 2020 May; 37(5):609-616. PubMed ID: 31782447
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of eIF-4E positively regulates formation of the eIF-4F translation initiation complex following DNA damage.
Zhang Y; Li Y; Yang DQ
Biochem Biophys Res Commun; 2008 Feb; 367(1):54-9. PubMed ID: 18164262
[TBL] [Abstract][Full Text] [Related]
14. Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor.
Iwasaki S; Floor SN; Ingolia NT
Nature; 2016 Jun; 534(7608):558-61. PubMed ID: 27309803
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of translation initiation as cancer therapeutics.
Lindqvist L; Pelletier J
Future Med Chem; 2009 Dec; 1(9):1709-22. PubMed ID: 21425987
[TBL] [Abstract][Full Text] [Related]
16. The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA.
Iwasaki S; Iwasaki W; Takahashi M; Sakamoto A; Watanabe C; Shichino Y; Floor SN; Fujiwara K; Mito M; Dodo K; Sodeoka M; Imataka H; Honma T; Fukuzawa K; Ito T; Ingolia NT
Mol Cell; 2019 Feb; 73(4):738-748.e9. PubMed ID: 30595437
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.
Rodrigo CM; Cencic R; Roche SP; Pelletier J; Porco JA
J Med Chem; 2012 Jan; 55(1):558-62. PubMed ID: 22128783
[TBL] [Abstract][Full Text] [Related]
18. Small-Molecule Inhibitors Targeting eIF4A in Leukemia.
Jia X; Zhou H
Curr Protein Pept Sci; 2021; 22(7):559-566. PubMed ID: 34042032
[TBL] [Abstract][Full Text] [Related]
19. Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma.
Kayastha F; Herrington NB; Kapadia B; Roychowdhury A; Nanaji N; Kellogg GE; Gartenhaus RB
Mol Med; 2022 Sep; 28(1):101. PubMed ID: 36058921
[TBL] [Abstract][Full Text] [Related]
20. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer.
Wolfe AL; Singh K; Zhong Y; Drewe P; Rajasekhar VK; Sanghvi VR; Mavrakis KJ; Jiang M; Roderick JE; Van der Meulen J; Schatz JH; Rodrigo CM; Zhao C; Rondou P; de Stanchina E; Teruya-Feldstein J; Kelliher MA; Speleman F; Porco JA; Pelletier J; Rätsch G; Wendel HG
Nature; 2014 Sep; 513(7516):65-70. PubMed ID: 25079319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
